Astria Therapeutics Soars 35.47% on Promising HAE Trial Results

On May 2, 2025, Astria Therapeutics saw a significant pre-market rise of 35.47%, driven by the publication of promising results from a Phase 1a trial of navenibart, a potential long-acting therapy for hereditary angioedema (HAE).

The trial, published in the Annals of Allergy, Asthma & Immunology, demonstrated that navenibart could provide effective attack prevention for HAE with dosing intervals of every 3 and 6 months. The results showed that for all doses of 300 mg or higher, the mean half-life of navenibart ranged from 82 to 105 days, supporting the potential for extended dosing intervals. The inhibition of plasma kallikrein activity by navenibart was statistically significant compared to placebo, further validating its therapeutic potential.

Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics, expressed enthusiasm about the publication, stating that it affirms the company's belief in navenibart's potential to become the first-choice therapy for HAE. The Phase 1a trial results have paved the way for the initiation of the pivotal Phase 3 trial, ALPHA-ORBIT, which is currently enrolling participants globally. This Phase 3 program aims to introduce a potentially life-changing therapy for eligible HAE patients worldwide.